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Abstract

Key Points

IMPORTANCE The diagnostic evaluation for Alzheimer disease may be improved by a blood-based
diagnostic test identifying presence of brain amyloid plaque pathology.

Question Is an amyloid probability
score based on a mass spectrometry–
based blood test measuring plasma
amyloid β 42:40 ratio and apoE

OBJECTIVE To determine the clinical performance associated with a diagnostic algorithm
incorporating plasma amyloid-β (Aβ) 42:40 ratio, patient age, and apoE proteotype to identify brain
amyloid status.

proteotype plus age, associated with
identifying brain amyloidosis among
patients with cognitive impairment?

DESIGN, SETTING, AND PARTICIPANTS This cohort study includes analysis from 2 independent

Findings In this cohort study of 686

cross-sectional cohort studies: the discovery cohort of the Plasma Test for Amyloidosis Risk

participants from 2 separate studies, the

Screening (PARIS) study, a prospective add-on to the Imaging Dementia–Evidence for Amyloid

developed Amyloid Probability Score

Scanning study, including 249 patients from 2018 to 2019, and MissionAD, a dataset of 437

showed high concordance with amyloid

biobanked patient samples obtained at screenings during 2016 to 2019. Data were analyzed from

PET status, with an area under the curve

May to November 2020.

of 0.88 and overall accuracy of 81%. The
test’s findings were significantly

EXPOSURES Amyloid detected in blood and by positron emission tomography (PET) imaging.

associated with the presence or absence
of brain amyloidosis as determined by

MAIN OUTCOMES AND MEASURES The main outcome was the diagnostic performance of plasma
Aβ42:40 ratio, together with apoE proteotype and age, for identifying amyloid PET status, assessed
by accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC).

positron emission tomography.
Meaning These findings suggest that
this blood test had robust performance
in detecting brain amyloidosis and could

RESULTS All 686 participants (mean [SD] age 73.2 [6.3] years; 368 [53.6%] men; 378 participants
[55.1%] with amyloid PET findings) had symptoms of mild cognitive impairment or mild dementia.
The AUC of plasma Aβ42:40 ratio for PARIS was 0.79 (95% CI, 0.73-0.85) and 0.86 (95% CI,

aid clinicians in the diagnosis of
Alzheimer disease among patients with
cognitive impairment.

0.82-0.89) for MissionAD. Ratio cutoffs for Aβ42:40 based on the Youden index were similar
between cohorts (PARIS: 0.089; MissionAD: 0.092). A logistic regression model (LRM) incorporating
Aβ42:40 ratio, apoE proteotype, and age improved diagnostic performance within each cohort
(PARIS: AUC, 0.86 [95% CI, 0.81-0.91]; MissionAD: AUC, 0.89 [95% CI, 0.86-0.92]), and overall
accuracy was 78% (95% CI, 72%-83%) for PARIS and 83% (95% CI, 79%-86%) for MissionAD. The

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

model developed on the prospectively collected samples from PARIS performed well on the
MissionAD samples (AUC, 0.88 [95% CI, 0.84-0.91]; accuracy, 78% [95% CI, 74%-82%]). Training
the LRM on combined cohorts yielded an AUC of 0.88 (95% CI, 0.85-0.91) and accuracy of 81% (95%
CI, 78%-84%). The output of this LRM is the Amyloid Probability Score (APS). For clinical use, 2 APS
cutoff values were established yielding 3 categories, with low, intermediate, and high likelihood of
brain amyloid plaque pathology.
(continued)
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Abstract (continued)

CONCLUSIONS AND RELEVANCE These findings suggest that this blood biomarker test could allow
for distinguishing individuals with brain amyloid–positive PET findings from individuals with
amyloid-negative PET findings and serve as an aid for Alzheimer disease diagnosis.
JAMA Network Open. 2022;5(4):e228392. doi:10.1001/jamanetworkopen.2022.8392

Introduction
Alzheimer disease (AD) is the most common form of dementia and is one of the greatest health
challenges for the 21st century.1 AD or related dementia affects approximately 50 million people
worldwide and 6.1 million people in the US, with 1 million more at early disease stages in the US. By
2060, the number of people with AD is estimated to reach 13.8 million people in the US.2 AD is
pathologically characterized by extracellular accumulation of amyloid-β (Aβ) in amyloid plaques,
intracellular accumulation of tau in tangles, neuronal and synaptic loss, brain atrophy, and
inflammation.3-6 Significant evidence suggests that Aβ peptides accumulate in the brain and
generate a cascade of events that results in neurodegeneration and clinical dementia of the
Alzheimer type.7-10
Early AD diagnosis and its differentiation from other dementias are imperative for early
treatment and prevention. AD diagnosis based on clinical criteria alone has insufficient sensitivity and
specificity, leading to high misdiagnosis rates among individuals with mild cognitive impairment. The
clinical sensitivity for AD diagnosis ranges from 70.9% to 87.3% whereas specificity ranges from
44.3% to 70.8%.11 Considerable progress over the last several decades in the development of
amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers has enabled
the detection of brain amyloid plaques that are necessary for an AD diagnosis.12 The Imaging
Dementia–Evidence for Amyloid Scanning (IDEAS) study13 demonstrated that incorporating amyloid
PET findings into the clinical evaluation of study patients changed the etiologic diagnosis from AD
to non-AD in 25.1% of patients and from non-AD to AD in 10.5% of patients, resulting in changes in
their clinical treatment plan after PET in 60.2% patients. While amyloid PET and CSF biomarker
measures have reduced misdiagnosis rates when used, broad-scale clinical implementation remains
challenging because of their high cost, patient avoidance of invasive diagnostic procedures or
radiation exposure, limited reimbursement, and restricted availability.
Several studies have shown that high-precision mass spectrometry (MS) assays for plasma
Aβ42 and Aβ40 levels can accurately detect brain amyloidosis as well as estimate conversion to brain
amyloid positivity approximately 5 years prior to a positive amyloid result in a PET scan.14-17 Recently,
we reported the analytical validation parameters and proof-of-principle clinical performance for a
blood test using high-resolution tandem MS to quantify plasma Aβ42 and Aβ40 concentrations and
to identify the presence or absence of plasma apolipoprotein E isoform-specific peptides (apoE
proteotype) along with patient age in detecting brain amyloid plaques.18,19 In this study, we report
the first application of this validated test, certified by the College of American Pathologists and
Clinical Laboratory Improvement Amendments of 1988, for measuring Aβ42:40 ratio and apoE in
samples from the discovery cohort of the Plasma Test for Amyloidosis Risk Screening (PARIS) study,
a subset of samples prospectively collected for the purpose of establishing test performance. The
collected data were used to develop an algorithm using Aβ42:40 ratio, apoE, and age to estimate the
amyloid PET status of patients. The developed algorithm was validated on biobanked samples from
MissionAD. A final algorithm was constructed combining the samples from both cohorts yielding the
Amyloid Probability Score (APS) for estimating brain amyloid PET status in adults aged at least 60
years with mild cognitive impairment (MCI) or mild dementia being evaluated for AD.
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Methods
For this cohort study, the PARIS and MissionAD studies were reviewed and approved by central or
local ethics and safety review committees or boards. All participants (or their legally authorized
representative) reviewed and signed an approved informed consent document. This study is
reported following the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) reporting guideline.

PARIS Study
Participants were prospectively enrolled into the PARIS study, a C2N-sponsored substudy of the
IDEAS study (ClinicalTrials.gov Identifier: NCT02420756). IDEAS evaluated the clinical utility of
amyloid PET in Medicare beneficiaries with MCI or dementia meeting Appropriate Use Criteria for
amyloid PET.13 The objective of the PARIS study was to establish and validate the clinical
performance of this MS-based blood test for identifying brain amyloid status as determined by
amyloid PET findings. Participants enrolled between October 1, 2018, and January 4, 2019, were
included in the PARIS discovery cohort analysis presented here. In the PARIS discovery cohort, 253
plasma samples were collected and analyzed for Aβ40 and Aβ42 concentrations and apoE peptides.
Of these, 249 patients-sample pairs had results from both PET images and blood samples.

MissionAD Study
The MissionAD consisted of 2 global phase 3 studies (ClinicalTrials.gov Identifier: NCT02956486)
that tested the safety and efficacy of elenbecestat (BACE inhibitor) in participants with MCI due to
AD or mild AD dementia with amyloid positivity confirmed by PET visual read or CSF test.20 A total
of 516 individual baseline screening plasma samples were selected to yield approximately 50%
positive prevalence of amyloid PET results defined by PET visual read. Of these plasma samples, 437
had corresponding amyloid PET performed under the same screening process within 80 days, and
these imaging results were used in the final data analysis. eTable 1 in the Supplement lists the
eligibility criteria for the 2 cohorts. For analyses of both PARIS and MissionAD samples, investigators
remained blinded to all patient demographic data and PET results until plasma analysis was
completed and data were locked. Race and ethnicity were self-reported at time of enrollment into
the studies according to the US Census Bureau race and ethnicity categories for use as demographic
variable in the analysis (PARIS) and per FDA guidance (MissionAD).

Amyloid PET Analysis
In the PARIS discovery cohort, 3 amyloid PET tracers were used: (18F)florbetapir (Amyvid; Lilly
Diagnostics), (18F)florbetaben (Neuraceq; Life Molecular Imaging) or (18F)flutemetamol (Vizamyl; GE
Healthcare). While in the IDEAS study, amyloid PET scans were interpreted visually by local
radiologists and nuclear medicine physicians, for PARIS, amyloid PET images were obtained and
processed by the American College of Radiology and analyzed by 2 board-certified radiologists with
amyloid PET tracer–specific training. In the MissionAD data set used for this study, 2 amyloid PET
tracers were used: (18F)florbetapir and (18F)florbetaben, and amyloid PET images were processed by
Bioclinica. Image analyses, including standardized uptake value ratio to Centiloid conversion, are
described in the eMethods in the Supplement. For purposes of determining eligibility for MissionAD,
PET visual read was used. Based on published evidence,21,22 we a priori defined amyloid positivity
for our analyses as Centiloid value greater than 25, which is a more sensitive threshold for brain
amyloid plaques than visual read.

Plasma Sample Analyses
Blood sample collection methods were similar between PARIS and MissionAD studies.18,20 MS-based
plasma Aβ42:40 ratio and apoE proteotype determination have been described previously18 and
outlined in the eMethods in the Supplement.
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Statistical Analysis
All data analyses were performed using R statistical software version 4.0.0 (R Project for Statistical
Computing). Binary logistic regression models (LRM) were used to estimate amyloid positivity based
on plasma Aβ42:40 ratio, apoE proteotype (encoded as presence of either 1 or 2 E4 alleles as well as
presence of E2 allele), and age. Detailed methods and algorithm development are described in
eMethods in the Supplement. P values were 2-sided, and statistical significance was set at α = .05.
Data were analyzed from May to November 2020.

Results
Demographic and Clinical Characteristics
Plasma samples for participants in the PARIS discovery cohort were collected from a total of 253
IDEAS participants, and of these, 249 participants had results from both PET images and blood
samples. For MissionAD, 437 out of the 516 baseline samples had corresponding Centiloid values for
amyloid PET, plasma Aβ42:40, apoE proteotype, and age, resulting in a total cohort of 686
participants (mean [SD] age, 73 [6.3] years; 368 [53.6%] men). All participants had symptoms of MCI
or mild dementia, and all participants had both amyloid PET scans and blood samples assessed. In
total, 378 participants (55.1%) had amyloid positive results on PET. Baseline characteristics for the
PARIS and MissionAD participants are summarized in Table 1.
Participant age, sex, and apoE proteotype frequencies were similar between the PARIS
discovery cohort and the included subset of MissionAD samples. The MissionAD cohort, compared
with the PARIS cohort, had more participants who were cognitively less impaired (defined as Mini
Mental State Examination score, 27-30; 250 participants [57.2%] vs 84 participants [48.6%]; Fisher
P = .06) and higher mean Mini Mental State Examination score (mean [SD] score, 26.8 [1.7] vs 24.7
[5.1]; t test P < .001), consistent with the finding that brain amyloidosis prevalence was lower in the
MissionAD cohort (217 participants [49.7%]) than the PARIS cohort (161 participants [64.7%]). The
MissionAD cohort, compared with the PARIS cohort, had more Asian participants (12 participants
[2.7%] vs 3 participants [1.2%]) and African American participants (25 participants [5.7%] vs 5
participants [2.0%]) and fewer White participants (393 participants [89.9%] vs 228 participants
[91.6%]). The most common amyloid PET tracer used in the combined cohorts was florbetaben (439
participants [64.0%]) followed by florbetapir (230 participants [33.5%]). Relatively few scans in the
PARIS cohort (17 participants [6.8%]) were obtained using flutemetamol.

Accuracy of Plasma Aβ42:40 Ratio Alone and With apoE and Age for Identifying
the Presence of Brain Amyloid Positivity
PARIS Cohort
Samples from the prospective PARIS study were analyzed first. In this cohort, the mean plasma
Aβ42:40 ratio was 7.6% (95% CI, 5.3%-8.6%) lower in the amyloid-positive than in the amyloidnegative group (P < .001; Figure 1A). Receiver operating characteristics analysis showed that a
plasma Aβ42:40 cutoff value of 0.089 maximized sensitivity and specificity (Youden index;
Figure 1A). The area under the curve (AUC) was 0.79 (95% CI, 0.73-0.85) (Figure 1D). Aβ42:40 ratios
plotted against Centiloid scores for all 249 patients showed that 77% of the patients were in the true
positive (137 participants) or true negative (55 participants) quadrants, indicating Aβ42:40 ratios
were concordant with amyloid PET status (Figure 1C). A smaller number of patients (22.9% total)
were classified as false positive (33 participants) or false negative (24 participants) (Figure 1C).
Sensitivity was 85% and specificity 63%. Positive predictive value (PPV) was 81%, and negative
predictive value (NPV) was 70%.
In addition to the plasma Aβ42:40 ratio, age and apoE proteotype were evaluated to aid in the
estimation of amyloid PET results. An LRM was constructed using plasma Aβ42:40 ratio, age, apoE
E4 copy number (1 or 2), and apoE E2 presence as variables to optimize estimation of brain amyloid
status compared with using plasma Aβ42:40 alone. eTable 3 in the Supplement lists the odds ratios
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for each of the inputs into the model trained on the PARIS discovery cohort. This LRM improved the
AUC to 0.86 (95% CI, 0.81-0.91) (Figure 1D) and overall accuracy to 78% (95% CI, 72%-83%). Model
estimation scores and their distributions for the amyloid PET-positive vs amyloid PET-negative
groups are shown in Figure 1B. The AUC for a model including just age and apoE (no Aβ) was
marginally better than plasma Aβ42:40 ratio alone in this data set, reaching 0.81 (95% CI, 0.76-0.87)
(Figure 1D). However, when age, apoE, and Aβ42:40 were combined, model performance
significantly improved compared with Aβ42:40 ratio alone (DeLong P < .001). Similarly, the full
model was significantly better than the model including just age and apoE (DeLong P = .007).
MissionAD Cohort
After completion of PARIS sample analysis, biobanked samples from MissionAD became available for
analysis. In this cohort, plasma Aβ42:40 ratio was 11.1% (95% CI 9.3%-12.3%) lower in the amyloid
PET-positive group than in the amyloid-negative group (P < .001), and AUC analysis indicated an

Table 1. Baseline Characteristics for PARIS and MissionAD Cohorts
Participants, No. (%)
Characteristic

PARIS (n = 249)

MissionAD (n = 437)

Combined (N = 686)

Age, mean (SD) [range], y

74.6 (5.7) [65-91]

72.4 (6.4) [60-85]a

73.2 (6.3) [60-91]

Men

143 (57.4)

225 (51.5)

368 (53.6)

Women

106 (42.6)

212 (48.5)

318 (46.4)

Dementia

77 (30.9)

17 (3.9)b

94 (13.7)

MCI

172 (69.1)

411 (94.1)b

583 (85.0)

27-30

84 (48.6)c

250 (57.2)

334 (54.8)

Mean (SD)

24.7 (5.1)c

26.8 (1.7)

26.2 (3.2)

Mean (SD)

52.3 (46.2)

42.8 (50.2)

46.2 (48.9)

Positive (>25)

161 (64.7)

217 (49.7)

378 (55.1)

Sex

Disease staging

MMSE score

Centiloid

Amyloid PET tracer
Florbetapir

177 (71.1)

53 (12.1)

230 (33.5)

Florbetaben

55 (22.1)

384 (87.9)

439 (64.0)

Flutemetamol

17 (6.8)

0

17 (2.5)

African American

5 (2.0)

25 (5.7)

30 (4.4)

American Indian

1 (0.4)

0

1 (0.1)

Asian

3 (1.2)

12 (2.7)

15 (2.2)

Pacific Islander

0

1 (0.2)

1 (0.1)

White

228 (91.6)

393 (89.9)

621 (90.5)

Race

Not reported

2 (0.8)

1 (0.2)

3 (0.4)

Otherd

0

5 (1.1)

5 (0.7)

Unknown

10 (4)

0

10 (1.5)

Abbreviations: Aβ, amyloid β; MCI, mild cognitive
impairment; MMSE, Mini-Mental State Examination;
PARIS, Plasma Test for Amyloidosis Risk Screening.
a

Although sample selection criteria for MissionAD
cohort included participants aged 50 years and older
at the time of sample collection, owing to sample
availability, only samples from participants aged 60
years and older were received and analyzed.

b

In the MissionAD cohort, 3 patients did not have a
diagnosis and 6 patients had diagnosis of “no criteria
met.”

c

The MMSE data set from the PARIS cohort had 76
missing values.

d

Patients self-reporting other race did not provide
further information.

apoE proteotype
E2/E2

0

2 (0.5)

2 (0.3)

E2/E3

15 (6)

31 (7.1)

46 (6.7)

E2/E4

8 (3.2)

9 (2.1)

17 (2.5)

E3/E3

116 (46.6)

210 (48.1)

326 (47.5)

E3/E4

80 (32.1)

158 (36.2)

238 (34.7)

30 (12)

27 (6.2)

57 (8.3)

Plasma Aβ42, mean (SD), pg/mL

E4/E4

47.0 (8.9)

45.6 (7.9)

46.1 (8.3)

Plasma Aβ40, mean (SD), pg/mL

542.1 (107.5)

504.3 (80.3)

518.0 (92.8)

Plasma Aβ42:40 ratio, mean (SD)

0.087 (0.007)

0.091 (0.009)

0.089 (0.009)
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Figure 1. Diagnostic Performance of Plasma Amyloid-β (Aβ)42:40 Ratio Alone and Combined With Age and apoE Proteotype
A Box and whisker plots of Aβ42:40 ratios

PARIS

MissionAD

0.14

0.14

0.12

0.10

0.08

0.06

0.12

0.10

0.08

0.06
PET negative

PET negative

0.08

PET positive

PET negative

MissionAD

PET positive

Combined

1.0

1.0

0.8

0.8

0.8

0.6
0.4

Probability score

1.0

Probability score

Probability score

0.10

Model probability scores

0.2

0.6
0.4
0.2

0

0.6
0.4
0.2

0
PET negative

0

PET positive

PET negative

PET positive

PET negative

PET positive

Correlation between Aβ42:40 ratio and Centiloid scores
PARIS

MissionAD

Combined

0.12

0.10

0.08

0.06

0.14

Plasma Aβ42:40 ratio

0.14

Plasma Aβ42:40 ratio

0.14

Plasma Aβ42:40 ratio

0.12

0.06

PET positive

PARIS

C

P <.001

Plasma Aβ42:40 ratio

P <.001

Plasma Aβ42:40 ratio

Plasma Aβ42:40 ratio

P <.001

B

Combined

0.14

0.12

0.10

0.08

0.06
0

50

100

150

0.12

0.10

0.08

0.06

200

0

50

Centiloid

100

150

200

0

Centiloid

50

100

150

200

0.8

1.0

Centiloid

D Receiver operating characteristics curves demonstrating model performance

MissionAD

Combined
1.0

0.8

0.8

0.8

0.6
0.4
Aβ42:40 ratio and age
Aβ42:40 ratio
Full model

0.2

Sensitivity, %

1.0

Sensitivity, %

Sensitivity, %

PARIS
1.0

0.6
0.4
0.2

0
0.2

0.4

0.6

1 – Specificity, %

0.8

1.0

0.4
0.2

0
0

0.6

0
0

0.2

0.4

0.6

0.8

1.0

1 – Specificity, %

0

0.2

0.4

0.6

1 – Specificity, %

A and B, PET positive indicates Centiloid greater than 25 in positron emission tomograph scans; PET negative, Centiloid of 25 or less; dotted blue line, cutoff value defined by the
Youden index for each cohort (A); points, individual patient ratios; bold lines, medians; boxes, IQRs; and whiskers, IQR × 1.5. B, Each plot shows the scores that were calculated using
the model trained on that cohort. C, Correlation between Aβ42:40 ratio and Centiloid scores for each of the cohorts. vertical dotted line indicates Centiloid of 25; horizontal dotted
line, cohort-specific cutoff value for the Aβ42:40 ratio defined by the Youden index for the Aβ42:40 ratio. Patients falling in the top left quadrant are true-negatives, and patients in
the bottom right corner are true-positives.
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optimal (Youden) plasma Aβ42:40 cutoff value of 0.092 (Figure 1A). In MissionAD, the AUC for
Aβ42:40 ratio alone was 0.86 (95% CI, 0.82-0.89) (Figure 1D). Figure 1C shows the concordance
between plasma Aβ42:40 and brain amyloid PET-positive or amyloid PET-negative status for all 437
patients, with 196 true positives (44.9%), 157 true negatives (35.9%), 63 false positives (14.4%), and
21 false negatives (4.8%). The overall accuracy was 81% (95% CI, 77%-84%). Sensitivity was 90%
(95% CI, 86%-94%), and specificity was 71% (95% CI, 65%-77%). PPV was 76% (95% CI, 70%-81%),
and NPV was 88% (95% CI, 83%-93%).
As expected, when age, apoE E4 (factor) and apoE E2 (presence) were added to plasma
Aβ42:40 ratio to construct an LRM, the performance improved (Figure 1B), with AUC reaching 0.89
(95% CI, 0.86-0.92; DeLong P = .002) and an overall accuracy of 83% (95% CI, 79%-86%). For
comparison, the AUC for just age, apoE E4 and apoE E2 was 0.79 (95% CI, 0.74-0.83; DeLong
P < .001) (Figure 1D). The model parameters are included in eTable 3 in the Supplement.

Validation of Model From PARIS Cohort on MissionAD Samples
The model developed on the PARIS cohort was applied to the samples from MissionAD to validate
the performance of the model generated on the prospectively collected samples on a novel data set
(Table 2). AUC and accuracy of the PARIS model was conserved when applied to the Mission AD
samples. Similarly, no significant changes were seen in sensitivity or specificity of the test (Table 2).
PPVs and NPVs changed in the expected directions considering the difference in amyloid prevalence
between the cohorts. The intercept and slope of the estimation model calibration curve shows that
the LRM-estimated risk was well calibrated to the observed prevalence in a new data set (eFigure 4 in
the Supplement).

Combined Analyses and the APS Score
To develop an LRM for clinical use, the data from both cohorts were combined to train a
comprehensive estimating algorithm. The Aβ42:40 ratio was a mean of 10.3% (95% CI, 8.7%-10.9%)
lower in the amyloid-positive group (P < .001) (Figure 1A). For the Aβ42:40 ratio, the optimal
sensitivity and specificity cutoff (Youden) was 0.089, leading to overall accuracy of 79% (95% CI,
75%-82%), sensitivity of 82% (95% CI, 78%-86%), and specificity of 74% (95% CI, 69%-79%)
(Figure 1A).
An LRM that included Aβ42:40 ratio, age, apoE E4 (factor, 1 or 2 alleles) and apoE E2 (presence)
was fitted on the combined data sets (Figure 1B and C, model did not take into account which cohort
the sample originated from). While the odds ratio for Aβ42:40 was conserved between all models,
the value of apoE inclusion was refined in the combined data set, owing to the increase in patients
with each of the various genotypes (eTable 3 and eFigure 1 in the Supplement). Values for apoE E2 did
not achieve statistical significance but was included in the final model since the direction of the
outcome in the model was consistent with the known protective association of apoE E2.23 AUC
improved to 0.88 (95% CI, 0.85-0.91), compared with AUC of 0.84 (95% CI, 0.81-0.87) when using
Aβ42:40 ratio alone (DeLong P < .001) (Figure 1D). For comparison, the AUC for just age, apoE E4

Table 2. Performance of Models Developed on PARIS and MissionAD Cohorts, and Validation of PARIS Model
on MissionAD
Training cohort, % (95% CI)a
PARIS

PARIS

MissionAD

Model applied to

PARIS

MissionAD

MissionAD

AUC

0.86 (0.81-0.91)

0.88 (0.84-0.91)

0.89 (0.86-0.92)

Accuracy

78 (72-83)

78 (74-82)

83 (79-86)

Sensitivity

76 (68-82)

73 (66-79)

88 (82-92)

Specificity

82 (72-89)

83 (77-87)

78 (72-83)

PPV

88 (82-93)

81 (74-86)

80 (74-85)

NPV

65 (55-74)

76 (70-81)

86 (81-91)

Abbreviations: AUC, area under the receiver operating
characteristic curve; NPV, negative predictive value;
PARIS, Plasma Test for Amyloidosis Risk Screening;
PPV, positive predictive value.
a
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and apoE E2 was 0.79 (95% CI, 0.76-0.83; DeLong P < .001). Based on this LRM, we derived the APS,
calculated from the output of the logistic regression by scaling the output from 0 to 1 to 0 to 100.
Since the prevalence of amyloid positivity in the selected samples from the MissionAD cohort
was 50% positive and 50% negative based on sample selection criteria, a population with 60%
prevalence was used to select APS cutoff values optimizing the test’s PPVs and NPVs. This prevalence
approximates the prevalence in the IDEAS study, a large, nationally representative cohort of patients
with MCI and mild dementia of unknown etiology. An intermediate APS range was implemented to
increase NPV and PPV. The optimal APS cutoff values were chosen to balance the tradeoff between
high accuracy and a low frequency of intermediate results. Based on the association between APS
cutoff values and PPV and NPV in a 60% prevalence population (eFigure 2 in the Supplement), 86%
agreement between the blood test and amyloid PET status provided an optimal compromise
between high overall accuracy and low frequency of intermediate scores. The lower APS cutoff was
defined as 35, and the upper cutoff was 58. Applying these APS cutoff values to the combined data
set (Figure 2), the algorithm correctly classified 199 of 226 participants with negative amyloid PET
findings to the low APS group and 303 of 365 participants with positive amyloid PET findings into the
high APS group, corresponding to 88% (95% CI, 83%-92%) NPV and 83% (95% CI, 79%-87%) PPV
(Table 3). A total of 95 participants (13.8%) fell into the intermediate category (Table 3). After
reweighting for 60% amyloid PET-positive prevalence, the NPV and PPV were both 86% (Table 3).
The following APS categories and applicable interpretations were defined: low APS (0-35),
consistent with a negative amyloid PET result and a low likelihood of amyloid plaques; intermediate
APS (36-57), does not distinguish between the presence or absence of amyloid plaques; and high
APS (58-100), consistent with a positive amyloid PET result and a high likelihood of amyloid plaques.
APS diagnostic performance was consistent, regardless of whether the intermediate data points
were excluded or counted as positive or negative (eTable 2 in the Supplement). Excluding
intermediate data points resulted in APS performance with sensitivity of 92% (95% CI, 88%-95%)
and a specificity of 77% (95% CI, 71%-71%). The overall accuracy of APS performance was reduced

Figure 2. Density Plot Showing the Distribution of the Amyloid Probability Score Results in the Combined Data
Set for Amyloid-Positive and Amyloid-Negative Patients
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from 85% (95% CI, 82%-88%) to 80% (95% CI, 77%-83%) when intermediate data points were
either counted as positive or negative, suggesting that the good diagnostic performance of the 2 APS
cutoff values did not simply result from not assigning a positive or negative classification to patients
with intermediate APS values. When subgroup analyses were performed, the diagnostic accuracy
was comparable, as patients were stratified by cohort, sex, amyloid tracer, clinical disease stage, apoE
E4 status, age, or race or ethnicity (eFigure 3 in the Supplement), further demonstrating that the
2-cutoff APS was robust and valid.

Discussion
In this cohort study, we developed and analytically validated MS-based assays that quantified the
Aβ42:40 ratio and determined apoE proteotype from a single plasma sample.19 Previously, we
reported that combining plasma Aβ42:40 ratio, apoE proteotype, and participant’s age was
associated with accurately identifying brain amyloid status in a collection of heterogenous cohorts.18
The research prototype of this assay was recently shown to be the best among 8 plasma Aβ42:40
assays in detecting anomalous brain Aβ status in a head-to-head comparison in samples from the
Swedish Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably (BIOFINDER)
study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI).17 In this study, findings from 2
additional independent cohorts demonstrate that our analytically validated MS-based blood test was
clinically valid for identifying the presence of brain amyloid plaque pathology compared with amyloid
PET findings as reference standard.
Increasing evidence has shown that plasma Aβ42:40 ratio has utility in detecting brain
amyloidosis. With the recent US Food and Drug Administration (FDA) approval of aducanumab, the
first AD-modifying treatment to receive such approval, and others expected soon to follow,
identification and proper diagnosis of patients eligible for treatment becomes critical for health care
systems to deliver such treatments in a timely and effective manner. A 2021 study by Mattke and
Hanson24 projected that under the current model of specialist referrals and diagnostic evaluation of
patients with cognitive impairment and dementia, patients would have to wait a mean of 50 months
to access newly available treatments. At the same time, the model estimated that when a bloodbased biomarker test was used to triage patients before referral to specialists, that wait time could be
shortened to 12 months.24
For the data presented in this study, amyloid PET was used as the reference standard for
determination of brain amyloid status. While visual read is the basis of FDA approval for tracers and
how eligibility in MissionAD was determined, multiple studies have shown that visual reads miss early
stages of amyloid accumulation.21,25,26 The optimal Centiloid threshold to detect earliest amyloid
accumulation has been reported as between 15 and 26 in various studies.21,27-31 Based on the
literature, we prospectively chose a Centiloid value of 25 as the cutoff for brain amyloid PET positivity
in our study.
The goal of the PARIS discovery cohort was to prospectively collect blood samples for the
purpose of developing this blood test. The LRM and the optimal inputs into the LRM were initially
developed on this cohort. As samples from MissionAD became available, the LRM was validated on
those samples. Analysis showed that the odds ratios for the various inputs into the model were highly

Table 3. Amyloid PET Result Distribution by APS Category in the Combined Data Sets and in the Expected
Population With 60% Prevalence
Combined data sets, No. (%) [95% CI]

Reweighted for 60% prevalence, %

APS level

Amyloid PET negativea

Amyloid PET positiveb

Amyloid PET negativea

Amyloid PET positiveb

Abbreviations: APS, Amyloid Probability Score; PET,
positron emission tomography.

Low (0-35)

199 (88.1) [83.1-92.0]

27 (11.9) [8.0-16.9]

86.3

13.7

a

Intermediate
(36-57)

47 (49.5) [39.1-59.9]

48 (50.5) [40.1-60.9]

43.9

56.1

Amyloid PET negativity was defined as Centiloid
value of 25 or less in PET scans.

b

High (58-100)

62 (17.0) [13.3-21.2]

303 (83.0) [78.8-86.7]

14.1

85.9

Amyloid PET positivity was defined as Centiloid value
of greater than 25 in PET scans.
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conserved between cohorts, and the 2 cohorts were combined to allow training of the LRM on a
larger data set with better representation of the various apoE isoforms.
The output of the LRM (the APS) represented the likelihood that a patient would belong to
either the amyloid positive or negative category. Patients with APS results in the range of 36 to 57
had an approximately 50% chance of amyloid positivity and were therefore assigned an intermediate
interpretation. The small number of patients expected to fall into this intermediate range
(approximately 14% based on results from our 686-patient study and tracking at approximately 15%
based on clinical experience reported by Monane et al32) was not deemed to compromise the clinical
usefulness of the APS result.

Limitations
This study has some limitations. The difference in Aβ42:40 ratio between patients with positive and
negative PET findings is small, leading to a potential concern that assay drift may cause
misclassification of patients based on the ratio. In our clinical use of this test, we continuously
monitored the performance of quality control samples for the Aβ42:40 ratio and have seen less than
1% drift in longer than 18 months of experience and more than 6000 measurements.
Another limitation is the low representation from IDEAS and MissionAD of patients from racial
or ethnic minority groups, including American Indian, Asian, African American, and Pacific Islander
individuals. Underrepresentation of racial and ethnic minority groups has been a long-standing issue
in clinical studies of AD, and we seek to address this through ongoing collaborations. The limited
number of apoE E2 carriers in the current cohorts may have resulted in an underestimate of its
weight in the final model. Large, ongoing cohort studies will elucidate the role of various
clinicodemographic variables on blood biomarker estimation models for brain amyloidosis.

Conclusions
The findings of this cohort study demonstrated excellent clinical performance and clinical validity of
this MS-based blood test for identifying brain amyloid pathology among individuals with MCI or mild
dementia undergoing evaluation for AD. This blood test generated a clinical diagnostic score, the
APS, that could aid physicians in the evaluation of their patients with memory changes. For example,
a low APS indicates a low likelihood of brain amyloid plaques and is inconsistent with an AD diagnosis
(ie, other causes of cognitive symptoms should be investigated that could lead to improved patient
outcomes). A high APS indicates a high likelihood of brain amyloid plaques and is consistent with an
AD diagnosis among patients with cognitive decline. Increased diagnostic accuracy has the potential
to improve comprehensive care plans, expedite access to appropriate therapies, increase
accessibility, and enhance patient-centered outcomes. As the science evolves, other blood
biomarkers will be evaluated for their ability to further enhance the diagnostic performance of the
APS to identify AD brain pathology among individuals with MCI and mild dementia.

ARTICLE INFORMATION
Accepted for Publication: February 28, 2022.
Published: April 21, 2022. doi:10.1001/jamanetworkopen.2022.8392
Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2022 Hu
Y et al. JAMA Network Open.
Corresponding Author: Tim West, PhD, C2N Diagnostics, 4340 Duncan Ave, St Louis, MO 63110
(twest@c2n.com).
Author Affiliations: C2N Diagnostics, St Louis, Missouri (Hu, Kirmess, Meyer, Holubasch, Knapik, Contois, Jackson,
Harpstrite, Verghese, Fogelman, Braunstein, Yarasheski, West); Departments of Neurology, Radiology &
Biomedical Imaging, University of California, San Francisco (Rabinovici); Center for Statistical Sciences, Brown
University School of Public Health, Providence, Rhode Island (Gatsonis, Hanna); Mallinckrodt Institute of
JAMA Network Open. 2022;5(4):e228392. doi:10.1001/jamanetworkopen.2022.8392 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User on 05/11/2022

April 21, 2022

10/13

JAMA Network Open | Neurology

Plasma Amyloid Probability Score to Estimate Amyloid PET Findings Among Adults With Cognitive Impairment

Radiology, Washington University School of Medicine, St Louis, Missouri (Siegel); Department of Public Health
Sciences, University of California, Davis (Whitmer); American College of Radiology, Reston, Virginia (Apgar); Eisai,
Woodcliff Lake, New Jersey (Kanekiyo, Kaplow, Koyama, Verbel); ConfluenceStat, Miami, Florida (Connor);
Department of Neurology, Washington University School of Medicine, St Louis, Missouri (Bateman, Holtzman).
Author Contributions: Drs Hu and West had full access to all of the data in the study and take responsibility for the
integrity of the data and the accuracy of the data analysis.
Concept and design: Hu, Meyer, Gatsonis, Whitmer, Bateman, Holtzman, Verghese, Fogelman, Braunstein,
Yarasheski, West.
Acquisition, analysis, or interpretation of data: Hu, Kirmess, Meyer, Rabinovici, Gatsonis, Siegel, Whitmer, Apgar,
Hanna, Kanekiyo, Kaplow, Koyama, Verbel, Holubasch, Knapik, Connor, Contois, Jackson, Harpstrite, Holtzman,
Verghese, Fogelman, Braunstein, Yarasheski, West.
Drafting of the manuscript: Hu, Kanekiyo, Verbel, Connor, Verghese, Yarasheski, West.
Critical revision of the manuscript for important intellectual content: Hu, Kirmess, Meyer, Rabinovici, Gatsonis,
Siegel, Whitmer, Apgar, Hanna, Kanekiyo, Kaplow, Koyama, Verbel, Holubasch, Knapik, Contois, Jackson,
Harpstrite, Bateman, Holtzman, Verghese, Fogelman, Braunstein, Yarasheski, West.
Statistical analysis: Gatsonis, Whitmer, Kanekiyo, Verbel, Connor, West.
Obtained funding: Verghese, Braunstein, Yarasheski, West.
Administrative, technical, or material support: Hu, Kirmess, Meyer, Kaplow, Koyama, Holubasch, Knapik, Contois,
Jackson, Harpstrite, Bateman, Verghese, Fogelman, West.
Supervision: Hu, Kirmess, Meyer, Holubasch, Jackson, Holtzman, Verghese, Fogelman, Braunstein,
Yarasheski, West.
Conflict of Interest Disclosures: Dr Meyer reported having a patent for US20180364260A1 pending to C2N
Diagnostics. Dr Rabinovici reported grants from the National Institutes of Health (NIH), American College of
Radiology, Alzheimer’s Association, Rainwater Charitable Foundation, Genentech, Avid Radiopharmaceuticals, GE
Healthcare, and Life Molecular Imaging; personal fees from El Lilly, Genentech, Eisai, Roche, and Johnson &
Johnson outside the submitted work; and serving as Associate Editor of JAMA Neurology. Dr Gatsonis reported
receiving grants from American College of Radiology during the conduct of the study. Dr Siegel reported grants and
personal fees from the American College of Radiology during the conduct of the study; grants from Blue Earth
Diagnostics, Curium Pharma, ImaginAb, and Progenics Pharmaceuticals and personal fees from Curium Pharma,
Progenics Pharmaceuticals, American Medical Foundation for Peer Review & Education, Avid
Radiopharmaceuticals, BTG Management Services, Capella Imaging, GE Healthcare, Huron Consulting Services,
Lantheus Medical Imaging, and Siemens Healthineers outside the submitted work. Dr Bateman reported being a
cofounder of C2N Diagnostics, of which Washington University has equity ownership interest, and a coinventor of
the stable isotope labeling kinetics and blood plasma assay technology licensed by Washington University to C2N
Diagnostics for which he receives royalties, and receiving personal fees from Roche, Genetech, AbbVie, Pfizer,
Boehringer-Ingelheim, Merck, and AC Immune and grants from Eisai and Roche outside the submitted work Dr
Holtzman reported receiving personal fees from Washington University and C2N Diagnostics during the conduct
of the study; serving as a cofounder with equity in C2N Diagnostics; receiving personal fees from Denali,
Genentech, Cajal Neurosciences, Eli Lilly, and Casma outside the submitted work; and having a patent for a
methods of determining amyloid beta turnover in blood, licensed to C2N Diagnostics. No other disclosures were
reported.
Funding/Support: This work was supported by the NIH (grant No. R44 AG059489), BrightFocus (grant No.
CA2016636), The Gerald and Henrietta Rauenhorst Foundation, and the Alzheimer’s Drug Discovery Foundation
(grant No. GC-201711-2013978). The IDEAS study was funded by the Alzheimer’s Association, the American College
of Radiology, Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and Company), GE Healthcare, and
Life Molecular Imaging (formerly Piramal Imaging). The Centers for Medicare & Medicaid Services provided
coverage for amyloid positron emission tomography scans under coverage with evidence development. Funding
for MissionAD study was provided by Eisai.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and
decision to submit the manuscript for publication.
Additional Contributions: The Alzheimer’s Association facilitated access to the IDEAS study.
REFERENCES
1. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020;16(3):391-460. doi:10.1002/alz.12068

JAMA Network Open. 2022;5(4):e228392. doi:10.1001/jamanetworkopen.2022.8392 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User on 05/11/2022

April 21, 2022

11/13

JAMA Network Open | Neurology

Plasma Amyloid Probability Score to Estimate Amyloid PET Findings Among Adults With Cognitive Impairment

2. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical
Alzheimer’s disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement. 2021;
17(12):1966-1975. doi:10.1002/alz.12362
3. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298(5594):789-791. doi:10.1126/science.
1074069
4. Morris JC. Clinical assessment of Alzheimer’s disease. Neurology. 1997;49(3)(suppl 3):S7-S10. doi:10.1212/WNL.
49.3_Suppl_3.S7
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to
therapeutics. Science. 2002;297(5580):353-356. doi:10.1126/science.1072994
6. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;
179(2):312-339. doi:10.1016/j.cell.2019.09.001
7. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for
the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712. doi:10.1038/nrd3505
8. Golde TE, Dickson D, Hutton M. Filling the gaps in the Aβ cascade hypothesis of Alzheimer’s disease. Curr
Alzheimer Res. 2006;3(5):421-430. doi:10.2174/156720506779025189
9. Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell.
2005;120(4):545-555. doi:10.1016/j.cell.2005.02.008
10. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat
Neurosci. 2015;18(6):800-806. doi:10.1038/nn.4018
11. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National
Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71(4):266-273. doi:
10.1097/NEN.0b013e31824b211b
12. Khoury R, Ghossoub E. Diagnostic biomarkers of Alzheimer’s disease: a state-of-the-art review. Biomarkers
Neuropsychiatry. 2019;1:100005. doi:10.1016/j.bionps.2019.100005
13. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with
subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or
dementia. JAMA. 2019;321(13):1286-1294. doi:10.1001/jama.2019.2000
14. Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future
brain amyloidosis. Neurology. 2019;93(17):e1647-e1659. doi:10.1212/WNL.0000000000008081
15. Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of
human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841-849. doi:10.
1016/j.jalz.2017.06.2266
16. Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s
disease. Nature. 2018;554(7691):249-254. doi:10.1038/nature25456
17. Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays
in Alzheimer disease. JAMA Neurol. 2021;78(11):1375-1382. doi:10.1001/jamaneurol.2021.3180
18. West T, Kirmess KM, Meyer MR, et al. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE
proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol
Neurodegener. 2021;16(1):30. doi:10.1186/s13024-021-00451-6
19. Kirmess KM, Meyer MR, Holubasch MS, et al. The PrecivityAD test: accurate and reliable LC-MS/MS assays for
quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain
amyloidosis. Clin Chim Acta. 2021;519:267-275. doi:10.1016/j.cca.2021.05.011
20. Roberts C, Kaplow J, Giroux M, Krause S, Kanekiyo M. Amyloid and APOE status of screened subjects in the
Elenbecestat MissionAD phase 3 program. J Prev Alzheimers Dis. 2021;8(2):218-223. doi:10.14283/jpad.2021.4
21. La Joie R, Ayakta N, Seeley WW, et al. Multisite study of the relationships between antemortem [11C]PIB-PET
Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 2019;15
(2):205-216. doi:10.1016/j.jalz.2018.09.001
22. van der Kall LM, Truong T, Burnham SC, et al. Association of β-amyloid level, clinical progression, and
longitudinal cognitive change in normal older individuals. Neurology. 2021;96(5):e662-e670. doi:10.1212/WNL.
0000000000011222
23. Insel PS, Hansson O, Mattsson-Carlgren N. Association between apolipoprotein E ε2 vs ε4, age, and β-amyloid
in adults without cognitive impairment. JAMA Neurol. 2021;78(2):229-235. doi:10.1001/jamaneurol.2020.3780
24. Mattke S, Hanson M. Expected wait times for access to a disease-modifying Alzheimer’s treatment in the
United States. Alzheimers Dement. Published online September 27, 2021. doi:10.1002/alz.12470

JAMA Network Open. 2022;5(4):e228392. doi:10.1001/jamanetworkopen.2022.8392 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User on 05/11/2022

April 21, 2022

12/13

JAMA Network Open | Neurology

Plasma Amyloid Probability Score to Estimate Amyloid PET Findings Among Adults With Cognitive Impairment

25. Whitwell JL, Xu J, Mandrekar JN, Gunter JL, Jack CR Jr, Josephs KA. Rates of brain atrophy and clinical decline
over 6 and 12-month intervals in PSP: determining sample size for treatment trials. Parkinsonism Relat Disord.
2012;18(3):252-256. doi:10.1016/j.parkreldis.2011.10.013
26. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh Compound-B positron emission
tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(Pt 7):2020-2033.
doi:10.1093/brain/awv112
27. Amadoru S, Doré V, McLean CA, et al. Comparison of amyloid PET measured in Centiloid units with
neuropathological findings in Alzheimer’s disease. Alzheimers Res Ther. 2020;12(1):22. doi:10.1186/s13195-02000587-5
28. Clark CM, Pontecorvo MJ, Beach TG, et al; AV-45-A16 Study Group. Cerebral PET with florbetapir compared
with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet
Neurol. 2012;11(8):669-678. doi:10.1016/S1474-4422(12)70142-4
29. Farrell ME, Jiang S, Schultz AP, et al; Alzheimer’s Disease Neuroimaging Initiative and the Harvard Aging Brain
Study. Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid
accumulation. Neurology. 2021;96(4):e619-e631. doi:10.1212/WNL.0000000000011214
30. Doré V, Bullich S, Rowe CC, et al. Comparison of 18F-florbetaben quantification results using the standard
Centiloid, MR-based, and MR-less CapAIBL approaches: validation against histopathology. Alzheimers Dement.
2019;15(6):807-816. doi:10.1016/j.jalz.2019.02.005
31. Navitsky M, Joshi AD, Kennedy I, et al. Standardization of amyloid quantitation with florbetapir standardized
uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14(12):1565-1571. doi:10.1016/j.jalz.2018.
06.1353
32. Monane M, Snider J, Drake J, et al. Early clinical utility data of a blood biomarker test in the evaluation of
patients with cognitive impairment. Innov Aging. 2021;5(suppl 1):1009. doi:10.1093/geroni/igab046.3585
SUPPLEMENT.
eMethods.
eFigure 1. Effects of Inputs into Model
eFigure 2. NPV and PPV at Various APS Values as Calculated for a Population With 60% Prevalence of PET Amyloid
Positivity
eFigure 3. Accuracy of APS in Subgroups of the Pooled Dataset
eFigure 4. Calibration of Model Developed on PARIS Discovery Cohort When Applied to MissionAD Cohort
eTable 1. Eligibility Criteria for PARIS Discovery and MissionAD
eTable 2. Diagnostic Performance of APS in the Pooled Dataset
eTable 3. Comparison of Odd Ratios for the Models Trained on PARIS Discovery, MissionAD, or the Combined
Cohorts

JAMA Network Open. 2022;5(4):e228392. doi:10.1001/jamanetworkopen.2022.8392 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User on 05/11/2022

April 21, 2022

13/13

